Amgen
3Q Revenues: $3.6 billion (flat)
3Q Earnings: $201 million (-81%)
YTD Revenues: $11.0 billion (+6%)
YTD Earnings: $2.3 billion (+10%)
Comments: Overall U.S. sales diminished 2% as Medicare reimbursement for Aranesp was lowered, while dosing questions impaired EU sales of the drug. Enbrel sales were up 16% to $821 million. Earnings took a $590 million hit to write off in-process R&D from a pair of acquisitions, as well as a $293 million charge as part of the company's restructuring program, and a $90 million inventory writeoff. Total restructuring charges are expected to reach $775-$850 million.
Magazine
